This is an aggregated industry headline. Read the full story at FierceBiotech →
Amenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling
With a panel of outside experts set to weigh in Thursday-and with a refusal-to-file fiasco with the FDA just barely in the rearview-Moderna and its contender for the United States' first mRNA-based influenza vaccine are heading into a critical test this week.
By FierceBiotech
· Jun 17, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed…
The WeekFierceBiotech ↗
Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was…
The WeekBriefing
Novartis’ Pluvicto won FDA approval on July 31 for use with ARPI therapy in PSMA-positive metastatic androgen …